ATX Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Amplia Therapeutics Ltd

Watchlist Manager

Watchlist

Price on Oct 14: 0.1 AUD

Market Cap: AU$51.3m

Prices of ASX stocks are not being updated. The latest ATX price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.

Profitability Summary

Amplia Therapeutics Ltd's profitability score is . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-166%

Negative 3Y Average Operating Margin

-191%

Operating Margin is Increasing

-243% > -166%

Negative Net Margin

-158%

Negative 3Y Average Net Margin

-186%

Net Margin is Increasing

-239% > -158%

Negative Free Cash Flow Margin

-267%

Negative 3Y Average Free Cash Flow Margin

-176%

Free Cash Flow Margin is Increasing

-316% > -267%

Negative ROE

-28%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-64%

Declining ROIC

-43% > -74%

View All Checks

Profitability Score

Margins, capital efficiency and cash flow, summed up in one score.

Create a free account · No card needed

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.